Skip to main content

Article Filters

Astrea Bioseparations expands manufacturing and warehousing capacity to support growing demand for its chromatography solutions in North America

Published date: 18 September 2023

Back to Article Listing

New 12,000 sq. ft. facility in Massachusetts will increase capacity for pre-packed column products and services and create up to 15 new full-time positions.

Cambridge, UK, 18 September 2023: Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.

The new ~12,000 sq. ft. facility allows Astrea Bio to bring its innovative products to customers within record lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders. The site expands the Company’s US footprint by over fourfold, supporting its continued growth trajectory as it also increases its workforce by up to 9% over an 18-month period.

Completing in Q4 2023, the facility, located in Canton, Massachusetts, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.

Dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the Company’s broad range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept® range of nanofiber-based purification technology for efficient production of cell and gene therapies.

Astrea Bio operates a global network of offices and manufacturing facilities, to ensure reliable supply of high-quality products. The Company’s 170 employees are located at its Cambridge, UK headquarters, manufacturing facilities in Gloucestershire, UK, the Isle of Man, Joliette, Canada and Canton, MA, alongside additional office facilities in Singapore.

Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” commented Chris Brown, Operations Director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high-quality products, within market-leading timeframes, as well as offering local technical expertise. 

About Astrea Bioseparations

Astrea Bioseparations (a Biotage company) is a leading provider of chromatography solutions for the life sciences industry. With products used in the manufacture of over 20 approved therapeutic and medical products, Astrea Bio is trusted by scientists around the world to deliver precise, reliable results. Astrea Bio is headquartered in Cambridge, UK with manufacturing facilities at the Isle of Man, British Isles, Joliette, Quebec and Massachusetts, USA.

FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Your basket

Your basket is empty. Continue shopping to add products to your basket.

Search our catalogue

Call Centre

Request Quote

Please enter a valid Email AddressPlease enter a valid Email AddressThe Email Address entered is already registered, please sign in with the Email Address or enter a different one

Please enter your NamePlease enter a valid Name, the maximum length is 65 characters.

Please enter a Contact NumberPlease enter a valid Contact Number, the maximum length is 30 characters.

Please enter your company name

Please enter the quantity of products you want a quote for

Please enter the date you need these products byPlease enter a date in the format DD/MM/YYYY

Astrea Bioseparations expands manufacturing and warehousing capacity to support growing demand for its chromatography solutions in North America

Published date: 18 September 2023

Back to Article Listing

New 12,000 sq. ft. facility in Massachusetts will increase capacity for pre-packed column products and services and create up to 15 new full-time positions.

Cambridge, UK, 18 September 2023: Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.

The new ~12,000 sq. ft. facility allows Astrea Bio to bring its innovative products to customers within record lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders. The site expands the Company’s US footprint by over fourfold, supporting its continued growth trajectory as it also increases its workforce by up to 9% over an 18-month period.

Completing in Q4 2023, the facility, located in Canton, Massachusetts, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.

Dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the Company’s broad range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept® range of nanofiber-based purification technology for efficient production of cell and gene therapies.

Astrea Bio operates a global network of offices and manufacturing facilities, to ensure reliable supply of high-quality products. The Company’s 170 employees are located at its Cambridge, UK headquarters, manufacturing facilities in Gloucestershire, UK, the Isle of Man, Joliette, Canada and Canton, MA, alongside additional office facilities in Singapore.

Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” commented Chris Brown, Operations Director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high-quality products, within market-leading timeframes, as well as offering local technical expertise. 

About Astrea Bioseparations

Astrea Bioseparations (a Biotage company) is a leading provider of chromatography solutions for the life sciences industry. With products used in the manufacture of over 20 approved therapeutic and medical products, Astrea Bio is trusted by scientists around the world to deliver precise, reliable results. Astrea Bio is headquartered in Cambridge, UK with manufacturing facilities at the Isle of Man, British Isles, Joliette, Quebec and Massachusetts, USA.

FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Call Centre Product Compare